Heim7CA • FRA
add
Camurus AB
Við síðustu lokun
60,80 €
Dagbil
61,05 € - 61,05 €
Árabil
41,28 € - 62,60 €
Markaðsvirði
39,13 ma. SEK
Meðalmagn
14,00
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
STO
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (SEK) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 553,13 m. | 47,67% |
Rekstrarkostnaður | 359,28 m. | -1,03% |
Nettótekjur | 146,98 m. | 1.066,60% |
Hagnaðarhlutfall | 26,57 | 754,43% |
Hagnaður á hvern hlut | 2,45 | 1.007,41% |
EBITDA | 164,05 m. | 1.057,04% |
Virkt skatthlutfall | 21,08% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (SEK) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 2,85 ma. | 139,75% |
Heildareignir | 3,76 ma. | 96,93% |
Heildarskuldir | 467,33 m. | 12,66% |
Eigið fé alls | 3,29 ma. | — |
Útistandandi hlutabréf | 58,64 m. | — |
Eiginfjárgengi | 1,08 | — |
Arðsemi eigna | 10,96% | — |
Ávöxtun eigin fjár | 12,47% | — |
Peningaflæði
Breyting á handbæru fé
| (SEK) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 146,98 m. | 1.066,60% |
Handbært fé frá rekstri | 103,25 m. | 244,05% |
Reiðufé frá fjárfestingum | -19,89 m. | -733,84% |
Reiðufé frá fjármögnun | 15,43 m. | 36,67% |
Breyting á handbæru fé | 101,44 m. | 181,88% |
Frjálst peningaflæði | 28,06 m. | -66,00% |
Um
Camurus AB is a Swedish research-based pharmaceutical and biotechnology company specialising in the commercialization of medicines for treating serious and chronic diseases. Established in 1991 and based in the southern university city of Lund, in the Medicon Valley region, the company is listed on Nasdaq Stockholm, Mid Cap.
Camurus was founded by scientists in biophysical, food, and pharmaceutical chemistry with expertise in lipid phase structures. The company provides nanoscale drug-delivery systems for development of high-value therapeutics. Wikipedia
Framkvæmdastjóri
Stofnsett
1991
Vefsvæði
Starfsfólk
247
